Workflow
Ironwood(IRWD) - 2025 Q2 - Quarterly Results
IronwoodIronwood(US:IRWD)2025-08-07 11:11

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance – LINZESS (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – – Plans to align with FDA on confirmatory Phase 3 trial design in Q4 2025 – – Progressing previously announced strategic alternatives review to maximize shareholder value – BOSTON, Mass., August 7, 2025 — Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotec ...